Given that the abnormal activation of Nrf2 is associated with thyroid cancer progression and chemoresistance (Li et al. 2021), targeting the Keap1‐Nrf2 pathway is considered a promising anticancer strategy. Here, NFE2L2 is linked to thyroid cancer.